Ban on Irrational Fixed-Dose Combination (FDC) Drugs

Context

The Union Government has prohibited 16 irrational Fixed-Dose Combination (FDC) medicines under Section 26A of the Drugs and Cosmetics Act, 1940, following expert recommendations that these formulations lacked proven therapeutic value and posed potential health risks. The move aims to strengthen patient safety, promote rational drug use, and curb antimicrobial resistance.

Understanding Fixed-Dose Combination (FDC) Medicines

What are FDC Drugs?

Meaning – Medicines containing two or more active pharmaceutical ingredients (APIs) in fixed proportions within a single dosage form such as tablets, capsules, syrups, or injections.
Objective – Designed to simplify treatment, improve patient compliance, and provide better therapeutic outcomes when supported by scientific evidence.

Why are FDCs Prescribed?

Better Patient Compliance – Reduces the number of medicines a patient needs to take.
Enhanced Clinical Effectiveness – Certain combinations provide superior therapeutic outcomes.
Treatment of Chronic Diseases – Commonly used for diabetes, hypertension, tuberculosis, HIV/AIDS, cardiovascular diseases, and bacterial infections.
Cost-Effective Therapy – Usually less expensive than purchasing individual medicines separately.

Why Were Certain FDCs Prohibited?

Lack of Scientific Evidence

Several combinations lacked sufficient clinical proof that combining the medicines improves treatment outcomes.
Example: Amoxicillin + Serratiopeptidase showed no established advantage over prescribing the antibiotic alone.

Higher Risk of Adverse Effects

Multiple active ingredients increase the possibility of drug interactions, toxicity, allergies, and unwanted side effects.

Contribution to Antimicrobial Resistance

Irrational antibiotic combinations promote the development of drug-resistant microorganisms, making infections harder to treat.

Questionable Dermatological Products

Many prohibited skin-care combinations containing vitamins, herbal extracts, and oils lacked scientific evidence of effectiveness.

Regulatory Framework

Drugs and Cosmetics Act, 1940

Provides the legal framework governing the manufacture, import, distribution, sale, and quality control of medicines in India.

Drugs Technical Advisory Board (DTAB)

India’s highest statutory scientific advisory body that evaluates the safety and therapeutic value of drug formulations.

Central Drugs Standard Control Organization (CDSCO)

India’s national drug regulator responsible for approving medicines, monitoring clinical trials, and enforcing drug quality standards.

Regulatory Process:

The Drugs and Cosmetics Act provides legal authority.
DTAB offers scientific recommendations.
CDSCO and the Central Government implement regulatory decisions.

Key Challenges

Threat to Public Health

Irrational drug combinations may expose patients to unnecessary medicines and increase health risks.

Rising Antimicrobial Resistance

Misuse of antibiotic combinations accelerates the emergence of drug-resistant infections.

Weak Enforcement

Some manufacturers attempt to reintroduce prohibited formulations with minor modifications.

Low Public Awareness

Self-medication and over-the-counter drug use continue despite associated risks.

Government Initiatives

Successive Ban on Irrational FDCs

2016 – 344 FDCs prohibited.
2018 – 328 additional FDCs restricted.
2024 – 156 more FDCs prohibited.
2026 – Latest prohibition covers 16 irrational FDCs, including antibiotics and dermatological formulations.

Scientific Approval Mechanism

Every new FDC must undergo rigorous clinical evaluation before receiving marketing approval.

Expert Scientific Review

DTAB-appointed committees periodically review marketed FDCs and recommend regulatory action.

Free Drugs Service Initiative (FDSI)

Implemented under the National Health Mission to promote essential generic medicines and discourage irrational combinations.

Public Awareness Measures

Doctors have been advised to recommend suitable alternatives and discourage patients from stopping medicines without medical consultation.

Way Forward

Evidence-Based Drug Approval

Approve only scientifically validated FDCs supported by robust clinical evidence.

Strengthen Market Surveillance

Prevent prohibited medicines from returning under modified names or formulations.

Increase Public Awareness

Educate people about the risks of irrational medicines and discourage self-medication.

Encourage Rational Prescribing

Promote single-drug therapy or clinically validated combinations wherever appropriate.

Adopt Global Standards

Align India’s drug regulatory practices with WHO recommendations and international best practices.

Strengthen Antimicrobial Stewardship

Integrate FDC regulation into India’s national strategy to combat antimicrobial resistance.

Ethical Dimensions

Patient Autonomy

Fixed combinations restrict physicians from tailoring doses to individual patient needs.

Beneficence and Non-Maleficence

Medical treatment should maximize benefits while minimizing harm; irrational combinations may violate this principle.

Public Health Responsibility

Inappropriate antibiotic combinations threaten society by accelerating antimicrobial resistance.

Commercial Ethics

Marketing unnecessary combinations for commercial gain increases healthcare costs and places avoidable financial burdens on patients.

Source : The Hindu